You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lyso-thermosensitive liposomal doxorubicin

Showing 1 - 25 of 1,636
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colon Cancer Liver Metastasis Trial in United States (Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution,

Terminated
Has Results
  • Colon Cancer Liver Metastasis
  • Lyso-Thermosensitive Liposomal Doxorubicin
  • +2 more
  • Los Angeles, California
  • +3 more
Sep 15, 2022

Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma Trial in Washington (Magnetic resonance high intensity focused ultrasound,

Recruiting
  • Pediatric Cancer
  • +9 more
  • Magnetic resonance high intensity focused ultrasound
  • Lyso-thermosensitive liposomal doxorubicin
  • Washington, District of Columbia
    Children's National Medical Center
Dec 10, 2021

Breast Cancer Trial in Prague, Haifa, Candiolo (drug, radiation, device)

Withdrawn
  • Breast Cancer
  • ThermoDox (Thermally Sensitive Liposomal Doxorubicin)
  • +2 more
  • Prague, Czechia
  • +2 more
Mar 29, 2022

Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma Trial (Magnetic Resonance-Guided High Intensity Focused Ultrasound,

Not yet recruiting
  • Solid Tumors
  • +8 more
  • Magnetic Resonance-Guided High Intensity Focused Ultrasound
  • Lyso-thermosensitive Liposomal Doxorubicin
  • (no location specified)
Mar 10, 2022

Metastatic Breast Cancer, Breast Cancer, Breast Tumors Trial in Utrecht (LTLD, MR-HIFU induced hyperthermia, Cyclophosphamide)

Recruiting
  • Metastatic Breast Cancer
  • +7 more
  • Utrecht, Netherlands
    University Medical Center Utrecht
Feb 16, 2021

Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV, Pancreatic Cancer Non-resectable Trial in Oxford (Focused

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +3 more
  • Focused Ultrasound
  • +2 more
  • Oxford, United Kingdom
    Oxford University Hospitals NHS Trust
Feb 22, 2022

Sarcoma, Soft Tissue Trial in Berlin, Munich (DPPG2-TSL-DOX)

Recruiting
  • Sarcoma, Soft Tissue
  • Berlin, Germany
  • +1 more
May 12, 2023

Metastatic Leiomyosarcoma, Metastatic Sarcoma, Metastatic Soft Tissue Sarcoma Trial (Computed Tomography, Magnetic Resonance

Not yet recruiting
  • Metastatic Leiomyosarcoma
  • +5 more
  • Computed Tomography
  • +3 more
  • (no location specified)
Feb 2, 2023

Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in

Recruiting
  • Fallopian Tube Carcinosarcoma
  • +28 more
  • Pegylated Liposomal Doxorubicin Hydrochloride
  • Peposertib
  • Aurora, Colorado
  • +7 more
Sep 2, 2022

Triple Negative Breast Cancer (TNBC) Trial in United States (Combination of liposomal doxorubicin)

Not yet recruiting
  • Triple Negative Breast Cancer (TNBC)
  • Combination of liposomal doxorubicin
  • Elizabeth, New Jersey
  • +7 more
Jul 13, 2023

Advanced Ovarian Cancer Trial in Spain (Olaparib, Pegylated Liposomal Doxorubicin)

Completed
  • Advanced Ovarian Cancer
  • Sabadell, Barcelona, Spain
  • +7 more
Jan 25, 2023

Breast Cancer With Liposomal Doxorubicin Regimen

Recruiting
  • Breast Cancer
  • +4 more
  • Liposomal doxorubicin containing regimen
  • Hangzhou, Zhejiang, China
    Second Affiliate Hospital of Zhejiang University
Feb 7, 2023

PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • L-DEP and PD-1 antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 8, 2023

Platinum-resistant Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
  • pegylated liposomal doxorubicin
  • (no location specified)
Aug 2, 2023

Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)

Recruiting
  • Breast Cancer
  • Pegylated liposomal doxorubicin
  • +5 more
  • Shanghai, China
    Shanghai Pudong Hospital
Dec 11, 2022

Angiosarcoma Metastatic Trial in Guangzhou (Abraxane combined with liposomal doxorubicin)

Recruiting
  • Angiosarcoma Metastatic
  • Abraxane combined with liposomal doxorubicin
  • Guangzhou, Guangdong, China
    Xing Zhang
Sep 4, 2022

Recurrent Ovarian Cancer Trial (DOXIL, Withaferin A, Ashwagandha)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • (no location specified)
Jan 27, 2023

Breast Cancer Trial in Paris, Barcelone, Madrid (Trastuzumab and non-pegylated liposomal doxorubicin)

Completed
Has Results
  • Breast Cancer
  • Trastuzumab and non-pegylated liposomal doxorubicin
  • Paris, France
  • +3 more
Feb 8, 2022

Breast Cancer Trial in Shanghai (sintilimab, bevacizumab biosimilar, pegylated liposomal doxorubicin)

Recruiting
  • Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
May 22, 2022

Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (biological, drug, other)

Active, not recruiting
  • Invasive Breast Carcinoma
  • Triple-Negative Breast Carcinoma
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 18, 2022

Locally Advanced or Metastatic Solid Tumors Trial in China (IN10018+PLD, IN10018+PLD+Toripalimab)

Active, not recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Anyang, Henan, China
  • +6 more
Apr 25, 2023

Kaposi Sarcoma, HIV-1-infection Trial (Pegylated liposomal doxorubicin, Paclitaxel)

Not yet recruiting
  • Kaposi Sarcoma
  • HIV-1-infection
  • (no location specified)
Jan 20, 2023

Solid Tumor, Colorectal Cancer, Cholangiocarcinoma Trial in France, United States (TRK-950, Irinotecan, Leucovorin)

Recruiting
  • Solid Tumor
  • +11 more
  • TRK-950
  • +14 more
  • Scottsdale, Arizona
  • +13 more
Oct 2, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in Santa Monica, Pittsburgh, Houston (TTI-622, Pegylated Liposomal

Recruiting
  • Ovarian Cancer
  • +5 more
  • TTI-622
  • Pegylated Liposomal Doxorubicin
  • Santa Monica, California
  • +4 more
Jul 26, 2022

Hemophagocytic Lymphohistiocytosis Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • Hemophagocytic Lymphohistiocytosis
  • L-DEP and PD-1 antibody
  • Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Apr 19, 2022